NCT03223610 2026-04-01
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
Clinical Trials
10 trialsNCT04588922 2026-03-16
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Sellas Life Sciences Group
Phase 1/2 Recruiting
NCT06510309 2026-03-13
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
Beth Israel Deaconess Medical Center
Phase 2 Recruiting
NCT07294677 2026-03-04
CAVALRY
University of Chicago
Phase 1/2 Recruiting
NCT04739813 2026-02-24
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT06712121 2026-02-02
Venetoclax and Decitabine in R/R T-ALL
Seoul National University Hospital
Phase 2 Recruiting
NCT04855695 2026-01-21
Avo In R/R And Previously Untreated MCL
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT05099471 2025-11-28
VIWA-1
University of Ulm
Phase 2 Recruiting
NCT06520098 2025-10-14
Benefit VA
VA Office of Research and Development
Phase 2 Recruiting
NCT06742463 2024-12-19
VHAG in Treating R/R T-ALL/LBL
First Affiliated Hospital of Zhejiang University
Phase 2 Recruiting